<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: To evaluate the impact of treatment on health states that affect patients' quality of life in advanced follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TwiST) analysis was performed on data from a phase III clinical trial (Marcus et al, 2008) </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: <z:chebi fb="0" ids="4027">Cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, and <z:chebi fb="0" ids="8382">prednisone</z:chebi> plus rituximab (R-CVP)-treated patients gained a mean of 15.17 months in TWiST, 8.33 months in Q-TwiST, and 11.30 months less in disease relapse, without increase in toxicity compared with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, and <z:chebi fb="0" ids="8382">prednisone</z:chebi> (CVP)-treated patients </plain></SENT>
<SENT sid="3" pm="."><plain>CONCLUSION: Rituximab plus CVP-treated patients reached a significant and clinically meaningful improvement within 12 months in quality-adjusted survival compared with CVP </plain></SENT>
</text></document>